Drug intelligence / Profile preview

CD34+ hematopoietic stem cells (Stanford University)

Development stage
Unknown
Lead developer
Stanford University
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intravenous
01

Overview

CD34+ hematopoietic stem cells (HSCs) are multipotent progenitor cells used in the treatment of high-risk non-Hodgkin lymphoma (NHL). In the specific protocol developed by Stanford University, these cells are utilized in a tandem transplantation approach. Patients first undergo autologous hematopoietic stem cell transplantation (auto-HSCT) following high-dose chemotherapy to rescue the bone marrow. This is followed by a non-myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) using donor CD34+ cells. The allogeneic phase employs a unique conditioning regimen consisting of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG), which is designed to promote donor cell engraftment and induce a graft-versus-lymphoma (GVL) effect while minimizing the risk of severe graft-versus-host disease (GVHD).

Other names
CD34+ cellsHematopoietic progenitor cellsPeripheral blood stem cellsPBSC

Beyond the preview

Go deeper on CD34+ hematopoietic stem cells (Stanford University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD34+ hematopoietic stem cells (Stanford University).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call